BellaSeno

ApplicationLeipzig, GermanyFounded 2017· One of 462 Application companies tracked by AMPulse

BellaSeno develops absorbable, implantable scaffolds that promote natural tissue regeneration, reducing the need for permanent implants and associated complications.

CEO / Founder: Dr. Mohit P. Chhaya
Team Size: 11-50
Stage: Active
Total Funding: $4.7M
Latest Round: Grant
Key Investors: Saxony Development Bank (SAB), European Fund for Regional Development (EFRE), Germany's Federal Ministry of Education and Research (BMBF), Australian government

Technology & Products

Key Products

BellaSeno develops next-generation fully absorbable breast scaffolds for breast reconstruction, augmentation, and revision surgeries. They focus on resorbable implants using biomimetic design and AI-driven additive manufacturing.

Technological Advantage

Proprietary scaffold formulations that enhance biocompatibility and reduce complications associated with permanent implants.

Differentiation

Value Proposition

Offers biocompatible and biodegradable absorbable scaffolds that integrate with the body's natural tissue to promote regeneration.

How They Differentiate

BellaSeno differentiates itself through its absorbable scaffold technology as opposed to permanent implants, offering a regenerative solution that integrates with natural tissue.

Market & Competition

Target Customers

Medical professionals, hospitals, and patients in need of breast reconstruction or other soft tissue repair procedures

Industry Verticals

Medical Devices, Tissue Engineering, Regenerative Medicine

Competitors

Permanent/silicone breast implant market (adjacent, not regenerative peers): AbbVie (Allergan), Establishment Labs, GC Aesthetics. Bioresorbable/regenerative soft-tissue scaffolds: Lattice Medical, Healshape, BioAesthetics, 4D Biomaterials. Note: Mentor Worldwide (J&J) is now exclusive global licensee/partner for BellaSeno's breast scaffold platform (June 2026), not a pure competitor.

Growth & Milestones

Growth Metrics

45+ patients clinical experience; longest follow-up up to 6 years; two-year positive breast scaffold data (83% mean volume retention, no major scaffold-related complications in FIH cohort); pivotal trial active (Jan 2026+); exclusive Mentor/J&J global license to accelerate market path; CE Mark targeted ~2028, FDA ~2030 per company roadmap

Major Milestones

Exclusive global licensing agreement with Mentor Worldwide LLC (J&J), June 2026, Positive two-year clinical trial results for breast scaffold (presented Aesthetic MEET 2026; no major scaffold-related complications in 19-patient first-in-human), Pivotal BRV-005 trial launched Jan 2026 (Australia); 30+ women treated across trials; 45+ patients clinical experience, up to 6-year follow-up, Prior: completed early clinical trials with positive one-year follow-up for breast and pectus scaffolds

Notable Customers

Clinical-stage; exclusive global licensee Mentor Worldwide LLC (J&J MedTech) for breast scaffold platform commercialization pathway. Prior tech partner Evonik; design tools SimScale. Not commercially available; products in clinical investigation only.

https://www.bellaseno.com

Why this company matters

AMPulse analysis, not a company disclosure

BellaSeno occupies a niche at the intersection of additive manufacturing and regenerative medicine, producing absorbable scaffolds designed to be replaced by the patient's own tissue over time. This contrasts with permanent silicone or saline implants, which carry long-term risks of capsular contracture, rupture, or revision surgery. The company's approach targets a clinical gap in breast reconstruction, augmentation, and revision, as well as chest wall deformities such as pectus excavatum.

The core technology uses polymer material extrusion (MEX) to fabricate scaffolds from proprietary biocompatible, biodegradable formulations. These scaffolds are designed with biomimetic architecture intended to support cell infiltration and vascularization. BellaSeno also applies AI-driven design optimization to tailor scaffold geometry to individual patient anatomy, and has used SimScale for simulation-based design validation. The Senella platform is the company's branded scaffold system for breast applications.

BellaSeno is a clinical-stage company. It has completed two clinical trials and reported positive one-year follow-up data for its resorbable breast and pectus excavatum scaffolds. The company partners with Evonik for materials and commercialization support, and has received funding from the Saxony Development Bank, the European Fund for Regional Development, the German Federal Ministry of Education and Research, and the Australian government. Its target customers include hospitals and surgeons performing breast reconstruction or soft tissue repair.

The company's primary differentiator is its fully absorbable scaffold technology, which eliminates the need for permanent hardware. However, it faces competition from other bioresorbable implant developers such as Lattice Medical, Healshape, and 4D Biomaterials, as well as from established permanent implant manufacturers like Abbvie and Establishment Labs. Key open questions include the scalability of its manufacturing process, the long-term mechanical performance of its scaffolds during degradation, and its ability to navigate EU medical device regulations for market entry.